Artemisia Vulgaris Root

Dosage for Artemisia Vulgaris Root is highly individualized and is not measured in milligrams like standard medications, but rather in Protein Nitrogen Units (PNU) or weight/volume (w/v) dilutions.

Diagnostic Testing

• Percutaneous (Prick) Testing: Usually performed using a 1:10 or 1:20 w/v concentration. A single drop is applied to the skin, and the skin is pricked through the drop.
• Intradermal Testing: If prick tests are negative, a more sensitive intradermal test may be used, typically starting at a much higher dilution (e.g., 0.02 mL of a 1:1000 or 1:10,000 w/v solution).

Immunotherapy (SCIT)

• Build-up Phase: Treatment begins with a very dilute solution (e.g., 1:100,000 w/v). Injections are given 1–2 times per week, with the dose increasing by 25% to 50% each time, provided no significant local reactions occur.
• Maintenance Phase: Once the 'Maintenance Dose' is reached (typically 0.5 mL of a 1:100 or 1:20 w/v concentration), the interval between injections is increased to every 2–4 weeks.

Artemisia Vulgaris Root extracts are used in children, generally starting at age 5. The dosing schedule for pediatric patients is typically the same as for adults, as the immune response is not strictly weight-dependent. However, healthcare providers may exercise extra caution and use slower build-up schedules for younger children to minimize the risk of systemic reactions.

Renal Impairment

No specific dose adjustments are required for renal impairment, as the systemic load of the protein extract is minimal. However, patients with severe renal disease may be at higher risk if epinephrine is required to treat an accidental systemic reaction.

Hepatic Impairment

No dosage adjustment is necessary for patients with hepatic impairment.

Elderly Patients

Elderly patients (over 65) should be evaluated for cardiovascular stability before beginning immunotherapy. The dose is the same, but the risk-benefit ratio must be carefully considered due to the potential for decreased physiological reserve during an anaphylactic event.

Artemisia Vulgaris Root extracts are never for self-administration at home. They must be administered in a clinical setting by a healthcare professional trained in the management of anaphylaxis.

1. 1Administration Site: Injections are given subcutaneously in the posterior aspect of the upper arm.
2. 2Observation Period: Patients must remain in the doctor's office for at least 30 minutes following an injection to monitor for signs of a systemic reaction.
3. 3Storage: Extracts must be kept refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Potency can be lost if the extract is left at room temperature for extended periods.
4. 4Activity: Patients should avoid vigorous exercise for 2 hours before and after the injection, as increased blood flow can accelerate allergen absorption.

If a dose is missed during the build-up phase, the next dose may need to be reduced or the previous dose repeated, depending on how much time has passed. If more than 4 weeks have passed since the last maintenance dose, the dose is usually reduced to ensure safety. Consult your allergist for a specific 'catch-up' schedule.

An 'overdose' in the context of allergenic extracts refers to the administration of a dose that exceeds the patient's current tolerance level.

• Signs: Rapid onset of hives (urticaria), swelling (angioedema), wheezing, shortness of breath, or a drop in blood pressure.
• Measures: Immediate administration of epinephrine (1:1000) intramuscularly, followed by antihistamines, corticosteroids, and emergency medical transport if necessary.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or skip appointments without medical guidance.

Most patients undergoing treatment with Artemisia Vulgaris Root will experience some form of local reaction. These are generally not dangerous but can be uncomfortable.

• Local Redness (Erythema): A red patch at the site of injection, usually appearing within minutes and lasting several hours.
• Local Swelling (Wheal): A raised, itchy bump at the injection site. If the swelling is smaller than the size of a half-dollar (approx. 3 cm), it is considered a normal response.
• Itching (Pruritus): Intense itching at the site of the skin test or injection.

• Large Local Reactions (LLR): Swelling that exceeds 5–10 cm in diameter. These may peak 6–12 hours after the injection and can cause significant discomfort or stiffness in the arm.
• Fatigue: Some patients report feeling unusually tired for several hours after an immunotherapy session.
• Mild Nasal Congestion: A slight increase in hay fever symptoms shortly after administration.

• Systemic Urticaria: Hives appearing on parts of the body other than the injection site.
• Gastrointestinal Distress: Nausea or abdominal cramping, which can be an early sign of a systemic allergic reaction.
• Headache: Persistent headache following administration has been reported in rare cases.

> Warning: Stop taking Artemisia Vulgaris Root and call your doctor immediately or seek emergency care if you experience any of these symptoms of anaphylaxis.

• Respiratory Distress: Wheezing, chest tightness, or difficulty breathing.
• Throat Tightness: A feeling of the throat closing or difficulty swallowing (laryngeal edema).
• Hypotension: Feeling faint, dizzy, or losing consciousness due to a rapid drop in blood pressure.
• Generalized Edema: Rapid swelling of the face, lips, or tongue.
• Cyanosis: A bluish tint to the lips or fingernails, indicating poor oxygenation.

There are no known long-term 'toxic' effects of Artemisia Vulgaris Root extracts on the organs (such as the liver or kidneys). The primary long-term risk is the development of new sensitivities, although immunotherapy is generally thought to prevent the development of new allergies in children. Some patients may develop persistent small nodules at the injection site if aluminum-precipitated extracts are used.

WARNING: RISK OF SEVERE ALLERGIC REACTIONS

Artemisia Vulgaris Root extracts can cause life-threatening systemic reactions, including anaphylaxis.

• Patients with unstable or severe asthma are at a significantly higher risk for fatal reactions.
• Extracts must only be administered by healthcare providers prepared to manage anaphylaxis.
• Patients should be prescribed an autoinjectable epinephrine device and instructed in its use.
• Immunotherapy may not be suitable for patients taking medications that could mask or complicate the treatment of anaphylaxis, such as beta-blockers.

Report any unusual symptoms to your healthcare provider immediately. Even a large local reaction should be reported before your next scheduled dose, as it may necessitate a dose adjustment.

Artemisia Vulgaris Root is a potent biological product. Safety depends on accurate diagnosis, proper storage, and meticulous administration. Patients must be aware that the 'dose' that was safe last week might cause a reaction this week if their underlying allergy symptoms are currently flared or if they have an acute infection.

No FDA black box warnings exist for the raw root itself as a botanical, but standardized and non-standardized allergenic extracts (the clinical form of Artemisia Vulgaris Root) carry a general class warning regarding Anaphylaxis. The warning emphasizes that administration must occur in a facility equipped with emergency supplies (oxygen, epinephrine, IV fluids) and by staff trained in emergency airway management.

• Allergic Reactions / Anaphylaxis Risk: This is the primary concern. Risk factors include a high level of sensitivity, rapid dose escalation, and administration during peak pollen season.
• Asthma Status: Patients must have their asthma well-controlled before receiving an injection. If a patient's Peak Flow is significantly below their personal best, the injection should be deferred.
• Infection: If a patient has a fever or a respiratory infection, the injection should be postponed, as the immune system is already in a state of heightened activation.
• Injection Technique: Accidental intravenous injection can cause immediate, severe anaphylaxis. Proper aspiration before injection is mandatory.

• Observation: A 30-minute post-injection wait is mandatory.
• Lung Function: For asthmatic patients, a pre-injection Peak Flow or FEV1 measurement is highly recommended.
• Skin Assessment: The injection site should be checked for large local reactions before the patient leaves the clinic.
• Symptom Diary: Patients are often encouraged to keep a log of any 'late' reactions that occur after they leave the office.

Artemisia Vulgaris Root does not typically cause sedation. However, if a patient experiences a systemic reaction or feels faint/dizzy after an injection, they should not drive until they have fully recovered and been cleared by a medical professional.

Alcohol should be avoided for several hours after an injection. Alcohol causes vasodilation (widening of blood vessels), which can potentially increase the rate of allergen absorption from the subcutaneous tissue, increasing the risk of a systemic reaction.

Immunotherapy is typically continued for 3 to 5 years. Stopping early may result in the return of allergy symptoms. There is no 'withdrawal syndrome' associated with stopping Artemisia Vulgaris Root, but the clinical benefits will gradually diminish over time if the full course is not completed.

> Important: Discuss all your medical conditions with your healthcare provider before starting Artemisia Vulgaris Root. Ensure they are aware of any history of heart disease or severe asthma.

• Beta-Blockers (Non-selective and Selective): Drugs like propranolol, metoprolol, or atenolol are generally contraindicated in patients receiving Artemisia Vulgaris Root immunotherapy. These drugs can make anaphylaxis more severe and, more importantly, can render epinephrine (the primary treatment for anaphylaxis) ineffective by blocking the beta-adrenergic receptors.
• MAO Inhibitors (MAOIs): Use of MAOIs can potentiate the effects of any sympathomimetic amines used to treat a reaction, potentially leading to a hypertensive crisis.

• ACE Inhibitors: Some studies suggest that patients on ACE inhibitors (like lisinopril) may be at an increased risk for more severe systemic reactions to allergenic extracts.
• Tricyclic Antidepressants (TCAs): Similar to MAOIs, TCAs can interfere with the body's response to emergency medications like epinephrine.

• Other Immunotherapy: If a patient is receiving multiple different extracts (e.g., Mugwort and Ragweed), the injections should be given in different arms, and the doses must be carefully tracked to avoid cumulative systemic load.
• Antihistamines: While not dangerous, taking a high-dose antihistamine before a skin test will cause a false negative result by suppressing the histamine-induced wheal and flare.

• Cross-Reactive Foods: Patients sensitive to Artemisia Vulgaris Root may experience 'Oral Allergy Syndrome' when eating celery, carrots, or certain spices (anise, coriander, cumin). While not a direct drug-food interaction, consuming these foods around the time of an injection may increase the overall 'allergic load' and should be discussed with a doctor.
• Caffeine: High intake of caffeine (a methylxanthine) might theoretically overlap with the methylxanthine-like properties mentioned in the EPC classification, potentially increasing heart rate or jitteriness when combined with the extract's adrenergic effects.
• High-Fat Meals: No known effect on the absorption of subcutaneous extracts.

• St. John's Wort: May affect the metabolism of secondary compounds in the extract, though clinical significance is low.
• Feverfew / Chamomile: These plants are in the same Asteraceae family as Artemisia. Taking supplements containing these may increase the risk of an allergic reaction in sensitive individuals.

• Skin Prick Tests: As mentioned, antihistamines, certain antidepressants (TCAs), and topical steroids can suppress the skin's reactivity, leading to inaccurate diagnostic results.
• Serum IgE Tests: Artemisia Vulgaris Root immunotherapy will cause a transient rise in specific IgE levels before they eventually decline; this must be interpreted correctly by the clinician.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any heart or blood pressure medications.

Artemisia Vulgaris Root extracts must NEVER be used in the following circumstances:

1. 1Severe, Uncontrolled Asthma: Patients with an FEV1 consistently below 70% of predicted value are at an unacceptably high risk of fatal bronchospasm during a systemic reaction.
2. 2Recent Myocardial Infarction or Unstable Angina: The physiological stress of anaphylaxis, or the administration of epinephrine to treat it, can be fatal in patients with unstable heart disease.
3. 3Previous Severe Anaphylaxis to this Specific Extract: If a patient has had a near-fatal reaction to Artemisia Vulgaris Root in the past, the risks of continuing therapy usually outweigh the benefits.
4. 4Beta-Blocker Therapy: Due to the inability to effectively treat anaphylaxis (as discussed in the interactions section).

Conditions requiring a careful risk-benefit analysis include:

• Pregnancy: While maintenance immunotherapy is often continued, starting a new course of Artemisia Vulgaris Root during pregnancy is generally avoided due to the risk of maternal anaphylaxis causing fetal hypoxia.
• Autoimmune Disorders: There is a theoretical concern that stimulating the immune system with allergenic extracts could exacerbate conditions like Lupus or Rheumatoid Arthritis.
• Malignancy: Patients with active cancer are generally not started on immunotherapy.
• Eosinophilic Esophagitis (EoE): Some evidence suggests that sublingual or subcutaneous immunotherapy might worsen or trigger EoE in predisposed individuals.

Artemisia Vulgaris is a member of the Asteraceae (Compositae) family. Patients with known severe allergies to the following may exhibit cross-sensitivity to Artemisia Vulgaris Root:

• Ragweed (Ambrosia)
• Dandelions
• Sunflowers
• Daisies
• Chrysanthemums
• Echinacea supplements

> Important: Your healthcare provider will evaluate your complete medical history, including your heart and lung health, before prescribing Artemisia Vulgaris Root.

Artemisia Vulgaris Root extracts are classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women.

• Risk Summary: The primary risk to the fetus is not the extract itself, but the potential for maternal anaphylaxis, which can lead to uterine contractions, placental abruption, or fetal hypoxia (lack of oxygen).
• Clinical Practice: Most allergists will continue a patient on a 'Maintenance' dose if they become pregnant, as the dose is already tolerated. However, they will not increase the dose during pregnancy, and they will almost never start a new patient on immunotherapy during gestation.

It is not known whether the allergenic proteins or metabolites from Artemisia Vulgaris Root are excreted in human milk. Because these are large proteins that are likely digested in the infant's gut, the risk to a nursing infant is considered very low. Breastfeeding is generally not considered a contraindication to receiving immunotherapy injections.

• Approved Age: Generally safe for children 5 years of age and older.
• Considerations: Children may have difficulty communicating the early symptoms of a systemic reaction (e.g., an 'itchy throat' or 'funny feeling'). Parents and clinicians must be extra vigilant during the 30-minute observation period.
• Growth Effects: There is no evidence that allergenic extracts affect growth or development.

• Safety Profile: Patients over 65 are at higher risk of complications from anaphylaxis due to pre-existing cardiovascular or pulmonary disease.
• Pharmacokinetics: Renal clearance of metabolites may be slower, but this rarely affects the immunological dosing of the extract.
• Polypharmacy: The higher likelihood of the patient being on beta-blockers or ACE inhibitors makes this population more complex to treat.

No specific studies have been conducted in patients with renal impairment. Because the total protein load per injection is extremely small (micrograms), no dose adjustment is typically required. However, clinicians should monitor the patient's overall fluid status and blood pressure if emergency treatment is required.

There are no specific recommendations for patients with hepatic impairment. The liver is not the primary site of action or elimination for allergenic proteins.

> Important: Special populations require individualized medical assessment. Always inform your specialist if you become pregnant or develop new health conditions during treatment.

Artemisia Vulgaris Root acts as an immunomodulator. Its primary molecular target is the IgE-FcεRI complex on mast cells and basophils (for diagnosis) and the T-cell receptor (TCR) on naive T-cells (for therapy).

During immunotherapy, the extract induces a shift in the cytokine milieu. It reduces the production of IL-4 and IL-5 (which promote IgE and eosinophils) and increases the production of IL-10 and TGF-beta (regulatory cytokines). This leads to 'B-cell switching,' where B-cells stop producing IgE and start producing IgG4. IgG4 acts as a 'decoy' or 'blocking' antibody that intercepts the Mugwort allergens before they can reach the IgE on mast cells.

Additionally, the provided data indicates Adrenergic alpha and beta agonist [MoA] properties. This suggests that components within the root may interact with G-protein coupled receptors (GPCRs) to modulate vascular permeability and smooth muscle tone, which may play a role in the local tissue response to the extract.

• Onset of Action (Diagnostic): 15–20 minutes for a skin prick test reaction.
• Onset of Action (Therapeutic): Clinical improvement in allergy symptoms typically requires 6–12 months of consistent immunotherapy.
• Duration of Effect: After a full 3–5 year course, the immunological 'memory' can provide relief for several years or even decades.

| Parameter | Value |

|---|---|

| Bioavailability | Low (Subcutaneous absorption is slow and localized) |

| Protein Binding | Minimal (Allergen-IgE/IgG binding is the primary interaction) |

| Half-life | Proteins: Hours; Immunological effect: Years |

| Tmax | 30–60 minutes (for systemic absorption of proteins) |

| Metabolism | Proteolysis by tissue macrophages and proteases |

| Excretion | Renal (as peptide fragments) |

• Composition: A complex mixture of proteins, glycoproteins, and polysaccharides. The major allergen is Art v 1, a 24-kDa protein.
• Solubility: Soluble in aqueous solutions and 50% glycerin.
• Molecular Weight: Ranges from 10 kDa to over 70 kDa for various allergenic fractions.

Artemisia Vulgaris Root is classified as a Non-Standardized Plant Allergenic Extract. It is related to other weed extracts such as Short Ragweed (Ambrosia artemisiifolia) and Russian Thistle (Salsola kali). Unlike 'Standardized' extracts (like Grass or Cat), the potency of Mugwort root is determined by weight/volume rather than bioequivalent allergy units.